HPTN 094 study examines a novel way to take addiction care and HIV prevention to people who inject drugs
Reports and Proceedings
Updates every hour. Last Updated: 1-May-2025 11:08 ET (1-May-2025 15:08 GMT/UTC)
Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 (“INTEGRA”) study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. The main findings from this randomized controlled trial that enrolled persons who inject drugs showed that similar numbers of participants were on medication for opioid use disorder (MOUD) and antiretroviral therapy (ART) for HIV care or prevention at 26 weeks post-randomization either to an intervention arm that provided integrated services with peer navigation in a mobile unit or to an active control arm that received navigation to integrated services at available community agencies only. Findings showed about seven percent of participants in both arms were determined as alive and on MOUD, about 35 percent of participants living with HIV were virally suppressed, and between three percent and five percent on HIV pre-exposure prophylaxis (PrEP) at 26 weeks post-randomization.
Socioeconomically disadvantaged groups may still be underusing emergency departments for potentially serious illnesses in the wake of the COVID pandemic, despite an overall rebound in emergency department use by 2022. Most of the rebound had been driven primarily by patients covered by commercial insurance or Medicare fee-for-service. When stratified by insurance type, however, the rebound was found to be significantly lower among patients covered by Medicaid or dual Medicare/Medicaid, who tend to be socioeconomically disadvantaged.